Company / Operating Cash Flow
Korro Bio, Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$60.1M
FY2025
5-year range
-$76.1M / $34.2M
FY2021-FY2025
Trend
+10.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$76M to -$60M over the past 3 years.
Based on SEC 10-K filings.
-$60M in FY2025.
Improved from -$76M to -$60M over the past 3 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 10.7% year-over-year.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$60.1M | +10.7% |
| FY2024 | -$67.3M | +11.5% |
| FY2022 | -$76.1M | -68.3% |
| FY2021 | -$45.2M | -232.1% |
| FY2020 | $34.2M | +334.1% |
| FY2019 | -$14.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026